Opioid receptor bronchial tree: Current science

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 3, 2014, Pages 191-199

  Krajnik, Malgorzata ^a   Jassem, Ewa ^b   Sobanski, Piotr ^c  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c Palliativzentrum Hildegard   (Switzerland)

Author keywords

C nerve fibers; Neurogenic inflammation; Opioid receptors; Pulmonary neuroendocrine cells

Indexed keywords

MORPHINE; OPIATE RECEPTOR;

DRUG EFFECTS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; NEUROSECRETORY CELL; NONMYELINATED NERVE; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT MUCOSA;

ADMINISTRATION, INHALATION; HUMANS; LUNG; MORPHINE; NERVE FIBERS, UNMYELINATED; NEUROENDOCRINE CELLS; RECEPTORS, OPIOID; RESPIRATORY MUCOSA; RESPIRATORY TRACT DISEASES;

EID: 84905734460     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000072     Document Type: Review

References (39)

1. Kong CF, Chew ST, Ip-Yam PC. Intravenous opioids reduce airway irritation during induction of anaesthesia with desflurane in adults. Br J Anaesth 2000; 85:364-367.
2. Passannante AN, Hazucha MJ, Bromberg PA, et al. Nociceptive mechanisms modulate ozone-Induced human lung function decrements. J Appl Physiol 1998; 85:1863-1870.
3. Ray NJ, Jones AJ, Keen P. Morphine, but not sodium cromoglycate, modulates the release of substance P from capsaicin-Sensitive neurones in the rat trachea in vitro. Br J Pharmacol 1991; 102:797-800.
4. Rogers DF, Barnes PJ. Opioid inhibition of neutrally mediated mucus secretion in human bronchi. Lancet 1989; 1:930-932.
5. Baroffio M, Crimi E, Rehder K, Brusasco V. Effects of k- and m-Opioid agonists on cholinergic neurotransmission and contraction in isolated bovine trachealis. Respir Physiol Neurobiol 2013; 185:281-286.
6. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: A pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage 2008; 36:29-38.
7. Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: A preliminary study. J Pain Symptom Manage 2005; 29:613-618.
8. Coyne PJ. The use of nebulized fentanyl for the management of dyspnea. Clin J Oncol Nurs 2003; 7:334-335.
9. Shohrati M, Ghanei M, Harandi AA, et al. Effect of nebulized morphine on dyspnea of mustard gas-Exposed patients: A double-Blind randomized clinical trial study. Pulm Med 2012; 2012:6109-6121.
10. Jennings AL, Davis AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57:939-944.
11. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990; 87:3294-3298.
12. Roth KA, Barchas JD. Small cell carcinoma cell lines contain opioid peptides and receptors. Cancer 1986; 57:769-773.
13. Cabot PJ, Dodd PR, Cramond T, Smith MT. Characterization of nonconventional opioid binding sites in rat and human lung. Eur J Pharmacol 1994; 268:247-255.
14. Krajnik M, Schäfer M, Sobański P, et al. Local pulmonary opioid network in patients with lung cancer: A putative modulator of respiratory function. Pharmacol Rep 2010; 62:139-149.
15. Krajnik M, Schäfer M, Sobański P, et al. Enkephalin, its precursor, processing enzymes, and receptor as part of a local opioid network throughout the respiratory system of lung cancer patients. Hum Pathol 2010; 41:632-642.
16. Mousa SA, Krajnik M, Sobański P, et al. Dynorphin expression, processing and receptors in the alveolar macrophages, cancer cells and bronchial epithelium of lung cancer patients. Histol Histopathol 2010; 25:755-764.
17. Cutz E, Pan J, Yeger H, et al. Recent advances and controversies on the role of pulmonary neuroepithelial bodies as airway sensors. Semin Cell Dev Biol 2013; 24:40-50. This is an excellent review on the recent findings in the biology of neuroepithelial body cells and their potential role as airway sensors.
18. 2 sensor in a human airway chemoreceptor cell line: Biochemical, molecular, and electrophysiological evidence. Am J Physiol Lung Cell Mol Physiol 2012; 303:L598-L607
19. Song H, Yao E, Lin C, et al. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci USA 2012; 109:17531-17536.
20. Gu X, Karp PH, Brody SL, et al. Chemosensory functions for pulmonary neuroendocrine cells. Am J Respir Cell Mol Biol 2014; 50:637-646.
21. Weichselbaum M, Sparrow MP, Hamilton EJ, et al. A confocal microscopic study of solitary pulmonary neuroendocrine cells in human airway epithelium. Respir Res 2005; 6:115.
22. Fu XW, Wang D, Pan Y, et al. Neuroepithelial bodies in mammalian lung express functional serotonin-Type 3 (5-HT3) receptor. Am J Physiol 2001; 281:L931-L940.
23. Lembrechts R, Brouns I, Schnorbusch K, et al. Neuroepithelial bodies as mechanotransducers in the intrapulmonary airway epithelium: Involvement of TRPC5. Am J Respir Cell Mol Biol 2012; 47:315-323..
24. Lembrechts R, Brouns I, Schnorbusch K, et al. Functional expression of the multimodal extracellular calcium-Sensing receptor in pulmonary neuroendocrine cells. J Cell Sci 2013; 126:4490-4501.
25. Dieplinger B, Gegenhuber A, Kaar G, et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010; 43:714-719.
26. Domnik NJ, Cutz E. Pulmonary neuroepithelial bodies as airway sensors: Putative role in the generation of dyspnea. Curr Opin Pharmacol 2011; 11:211-217.
27. 2+-Dependent secretion in human small-Cell lung carcinoma cells. J Neurosci 1996; 16:3672-3684.
28. Assas BM, Pennock JI, Miyan JA. Calcitonin gene-Related peptide is a key neurotransmitter in the neuro-Immune axis. Front Neurosci 2014; 8:23; eCollection 2014.
29. Grace MS, Baxter M, Dubuis E, et al. Transient receptor potential (TRP) channels in the airway: Role in airway disease. Br J Pharmacol 2014; 171:2593-2607
30. McGarvey LP, Butler CA, Stokesberry S, et al. Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthma. J Allergy Clin Immunol 2014; 133:704.e4-712.e4.
31. 2+ influx in human airway epithelial cells. J Biochem Mol Toxicol 2012; 26:179-186.
32. Sadofsky LR, Ramachandran R, Crow C, et al. Inflammatory stimuli upregulate transient receptor potential vanilloid-1 expression in human bronchial fibroblasts. Exp Lung Res 2012; 38:75-81.
33. Thomas KC, Roberts JK, Deering-Rice CE, et al. Contributions of TRPV1, endovanilloids, and endoplasmic reticulum stress in lung cell death in vitro and lung injury. Am J Physiol Lung Cell Mol Physiol 2012; 302:L111-L119.
34. Endres-Becker J, Heppenstall PA, Mousa SA, et al. mOpioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol 2007; 71:12-18.
35. Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: A comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage 2009; 38:747-757.
36. Krajnik M, Podolec Z, Zylicz Z, et al. Air humidity may influence the aerosol distribution of normal saline administered by closed or vented nebulizers operated continuously or dosimetrically. J Aerosol Med Pulm Drug Deliv 2009; 22:29-34.
37. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-Butanol (NNAL) by human UDP-Glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000; 28:1352-1360.
38. Yamada H, Ishii K, Ishii Y, et al. Formation of highly analgesic morphine-6- glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci 2003; 28:395-401.
39. Bouw MR, Tunblad K, Hammarlund-Udenaes M. Blood brain barrier transport and brain distribution of morphine-6-Glucuronide in relation to the antinociceptive effect in rats - pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 2001; 134:1796-1804